MetaCap

Fennec Pharmaceuticals Inc. (FENC)

NASDAQ: FENCHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

13.09-0.36 (-2.68%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

FENC stock chart

Technical analysis

Key statistics

All statistics
Market cap
$462.14M
P/E (TTM)
436.33
52-week range
5.65 – 13.85
Day range
12.64 – 13.55
Volume / Avg
398.14K / 220.87K
Beta
—

52-week range

$5.65$13.85

FENC stock today

Shares of Fennec Pharmaceuticals (FENC) finished lower on Nov 20 at $13.09, a drop of 2.68% or $0.36 per share, versus the S&P 500's 3.70% decline. At this level, FENC sits near the top of its 52-week range of $5.65 to $13.85: 5.5% below the high, set on Nov 18, 2026 and 131.7% above the low. FENC is up 70.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 66.1%.

Fennec Pharmaceuticals trades at 436.3x its trailing twelve-month earnings per share of $0.03. Its forward P/E of 12.5x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Fennec Pharmaceuticals

Company profile

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Jeffrey S. Hackman
Headquarters
Research Triangle Park, NC
Employees
35

Financial highlights

Full financials

In fiscal 2025, Fennec Pharmaceuticals generated $44.6 million in revenue, down 6.1% from fiscal 2024, the first decline in the 28 years shown. Fennec Pharmaceuticals reported a net loss of $9.7 million, compared with a loss of $436,000 a year earlier. Operating margin was -14.1%.

Fennec Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$44.64M$47.54M$21.25M$1.53M—
Growth-6.09%+123.69%+1284.50%——
Net income$-9.74M$-436.00K$-16.05M$-23.71M$-17.35M
EPS (diluted)$-0.34$-0.02$-0.60$-0.90$-0.67

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$17.60+34.45%

  • Strong buy 1
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $16.00High $19.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$0.12 vs $0.09
Surprise
+33.33%

FENC news

All FENC news

Fennec Pharmaceuticals peers

Health Care sector
FENC peer companies
CompanyPrice% ChgMarket capCompare
RGNXREGENXBIO Inc.7.16-0.28%$473.44Mvs FENC
SANASana Biotechnology Inc.1.59-8.62%$476.42Mvs FENC
DNAGinkgo Bioworks Holdings Inc. Class A7.46-9.02%$483.54Mvs FENC
VALNValneva SE ADR5.16-3.82%$490.86Mvs FENC
IRLAIRulya Therapeutics Inc.39.88-0.15%$432.36Mvs FENC
PROKProKidney Corp. Class A1.04-1.89%$415.21Mvs FENC
ETRAElectra Therapeutics Inc.8.11-9.28%$509.85Mvs FENC
TECXTectonic Therapeutic Inc.20.73-1.47%$405.26Mvs FENC

Indexes, lists and sector

Fennec Pharmaceuticals stock FAQ

What is Fennec Pharmaceuticals's stock price today?

FENC last traded at $13.09 as of Nov 20, 4:00 PM EST, down 2.68% on the day. Prices are delayed at least 15 minutes.

What is FENC's P/E ratio?

FENC trades at a trailing P/E ratio of 436.33 and a forward P/E of 12.47.

Who is Fennec Pharmaceuticals's CEO?

Mr. Jeffrey S. Hackman is the chief executive officer of Fennec Pharmaceuticals Inc., which has about 35 employees.

What is the FENC 52-week high?

The 52-week high for FENC is $13.85 and the 52-week low is $5.65. The stock is currently 5.5% below its high.

Compare FENC